New Frontiers for Chinese Biotech: Overcoming Challenges and Embracing Opportunities, New Journeys for Chinese Biotech!
As a key co-organizer, Biolink Capital-Clinical Service Center spearheaded the forum titled "New Frontiers for Chinese Biotech: Overcoming Challenges and Embracing Opportunities, New Journeys for Chinese Biotech!" The forum was moderated by Ken CHEN, VP of CSC and head of Biolink Capital, and featured high-profile industry leaders such as Yang Jianguo, CEO of PROXYBio; Jiang Fei, Chief Investment Officer (China) at China Medical System; Wang Xin, APAC BD Director at Servier; and Cai Jiaqiang, CSO of Medilink Therapeutics. The panel delivered deep insights into global licensing trends and shared strategies for international expansion, offering valuable perspectives for Chinese biotech companies navigating the global market. The discussions also highlighted strategies for weathering industry challenges and explored new models of collaboration between multinational corporations and innovative Chinese drug companies.
A highlight of the BD forum was a special session where innovative pharmaceutical companies showcased their latest drug projects. Notable industry figures in attendance included Wang Zhe, Founder of LWBP; Chen Xiaowu, VP of Medicinal Chemistry at CUREGENE; Huang Tongge, Chairman of Tohongkangheng; Cai Xianghai, VP of R&D at NOVATIM; Ye Yangliang, General Manager of Suzhou Zhuguang Biotech; Deng Yijun, Founder & CSO of MetCura Pharmaceuticals; He Linfu, VP & CTO of MicroDiag Biomedicine; Xing Li, Founder & CEO of LEXBIO; and Zhang Hailong, General Manager of Yongxin Biotech. Biolink Capital showcased 60 high-quality assets, drawing significant attention during the roadshow forum.
Amid the current volatility in China's pharmaceutical industry, the growing trend of collaboration among companies to overcome shared challenges is becoming increasingly evident. The BD forum is expected to inspire innovation and foster new perspectives, helping participants to identify ideal partners, expand market influence, and unlock new opportunities for growth and innovation.
